Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Kaleido Biosciences Inc

(NASDAQ: KLDO)
Add to Portfolio
unch (unch)
as of Sep 19, 2019

Last 9.52
Change unch (unch)
Open 9.34
Prev. Close 9.52
Today's Range
9.00
9.81
52wk Range
6.23
19.00
Volume 223,741
Avg Volume 80,482
Sector Medical - Biomedical

Perfomance Comparison

Name Today 3-Month 1-Year
KLDO unch +1.71% -33.10%
DJIA -0.19% +0.87% +2.61%
S&P 500 unch +0.46% +3.40%

Key Statistics

Annual EPS N/A
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 269,090
Weighted Alpha -39.63
Standard Deviation unch
Profit Margin N/A
Beta N/A

Growth Rates

YTD -33.10%

Opinion

Sell Hold Buy

Recent Headlines

Kaleido Biosciences to Present at the Morgan Stanley

GlobeNewswire via COMTEX - Thu Aug 29, 08:00AM EDT
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that management will part(full story)
MS: 44.02 (-0.34), KLDO: 9.52 (unch)

Kaleido Biosciences Announces Appointment of Theo

GlobeNewswire via COMTEX - Mon Jul 15, 08:00AM EDT
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that The(full story)
EVLO: 8.16 (-0.56), KLDO: 9.52 (unch)

Kaleido Biosciences Announces Closing of Initial

GlobeNewswire via COMTEX - Mon Mar 04, 04:22PM EST
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today an(full story)
MS: 44.02 (-0.34), KLDO: 9.52 (unch)

Nasdaq Welcomes Kaleido Biosciences, Inc. (Nasdaq:

GlobeNewswire via COMTEX - Thu Feb 28, 11:30AM EST
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the potential of the microbiome organ to treat disease and improve human health, (full story)
NDAQ: 101.68 (-0.94), KLDO: 9.52 (unch)

Kaleido Biosciences Announces Pricing of Initial

GlobeNewswire via COMTEX - Wed Feb 27, 07:27PM EST
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today an(full story)
MS: 44.02 (-0.34), KLDO: 9.52 (unch)